Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky

PR Newswire

NEW YORK, Nov. 16, 2026

TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholders who lost money.

NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Sellers drove Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares sharply lower on November 9, 2026, after the Company reported third-quarter TRYNGOLZA sales of $9.3 million and cut the drug's full-year sales guidance to roughly $50 million from $100-$110 million. If you bought IONS and are now holding losses, you may have legal rights, and Levi & Korsinsky is investigating. IONS shareholders who lost money are encouraged to submit their loss details for a free review . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP

Ionis beat consensus estimates on both revenue and earnings per share. Shares fell anyway. Third-quarter commercial revenue rose 18% year over year, which the Company attributed primarily to DAWNZERA product sales. TRYNGOLZA sales, however, were only $9.3 million, compared with $31.8 million in the third quarter of 2025.

TRYNGOLZA recorded approximately $32 million in first-half 2026 sales. To reach the prior $100-$110 million target, the drug needed roughly $68-$78 million over the final six months. The third quarter delivered $9.3 million. The revised full-year figure of roughly $50 million sits $50-$60 million below the original range.

If you are holding IONS losses after the November 9 sell-off, see if you may be eligible to recover your IONS losses or call (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the IONS Investigation

Q: How much did IONS stock drop? A: IONS shares fell roughly $7.27, or about 18.44% to open at approximately $32.15 on November 9, 2026, after the Company disclosed that it had cut its full-year 2026 TRYNGOLZA product sales guidance by roughly 50%, from $100-$110 million to approximately $50 million. By midday the stock had fallen more than 25% from the November 6 closing price. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Ionis Pharmaceuticals, Inc. made materially false or misleading statements regarding TRYNGOLZA's commercial performance and expected 2026 product sales. When the Company disclosed third-quarter TRYNGOLZA sales of $9.3 million and a reduced full-year outlook, the stock price declined sharply.

Q: When did Ionis Pharmaceuticals allegedly mislead investors? A: The investigation concerns statements made before the November 9, 2026 disclosure that allegedly caused investors to purchase IONS securities at inflated prices.

Q: What do IONS investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my IONS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought IONS and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-inc-ions-securities-investigation-notice---levi--korsinsky-302939311.html

SOURCE Levi & Korsinsky, LLP